Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting mai 3, 20220CommentsEN Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA avril 29, 20220CommentsEN NL Read More
Oxurion Announces Upcoming Preclinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting avril 11, 20220CommentsEN Read More
Oxurion Announces Extraordinary and Annual Shareholders’ Meetings avril 1, 20220CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following EUR > 10 million Private Placement and conversion notice from NEGMA mars 30, 20220CommentsEN NL Read More
Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG mars 17, 20220CommentsEN NL Read More
Noteringsprospectus – 8 maart 2022 mars 8, 20220CommentsProspectus voor de toelating tot de handel op Euronext Brussels van maximaal 9.156.635 nieuwe aandelen Read More
Listing Prospectus – March 8, 2022 mars 8, 20220CommentsProspectus for the admission to trading on Euronext Brussels of up to 9,156,635 new shares Read More
Vergadering Raad van Bestuur – 7 maart 2022 mars 7, 20220CommentsBijzonder verslag Raad van Bestuur inzake de uitgifte van nieuwe aandelen dd. 3 maart 2022 Bijzonder verslag Commissaris inzake de uitgifte van nieuwe aandelen dd. 4 maart 2022 Notulen van de vergadering van de Raad van Bestuur van 7 maart 2022 Read More
Board of Directors’ Meeting – March 7, 2022 mars 7, 20220CommentsSpecial report Board of Directors regarding issuance of new shares of March 3, 2022 Special report Statutory Auditor regarding issuance of new shares of March 4, 2022 Minutes of the Board of Directors’ meeting held on March 7, 2022 (Dutch only) Read More
Oxurion succesfully raises EUR >10 MILLION from leading US and European healthcare investors in a private equity placement mars 3, 20220CommentsEN NL Read More
Oxurion NV announces 2021 Full Year Results and 2022 Outlook février 22, 20220CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA février 22, 20220CommentsEN NL Read More
Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference février 14, 20220CommentsEN Read More
Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference février 11, 20220CommentsEN Read More
Oxurion to Participate in the 2022 BIO CEO and Investor Conference février 8, 20220CommentsEN Read More
OXURION to Participate in the 10th edition of Degroof Petercam’s Healthcare Conference janvier 18, 20220CommentsEN Read More
